<DOC>
	<DOCNO>NCT01678898</DOCNO>
	<brief_summary>This first human treatment PRX-102 , enzyme develop long-term enzyme replacement therapy patient confirm diagnosis Fabry disease ( alpha galactosidase deficiency ) . The safety , tolerability , exploratory efficacy evaluate study increase dos . Patients treat infusion every two week 12 week ( 7 infusion ) .</brief_summary>
	<brief_title>Dose-ranging Study PRX-102 Adult Fabry Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Symptomatic adult Fabry patient ( ≥18 yrs ) Males : plasma and/or leucocyte alpha galactosidase activity ( activity assay ) less low limit normal ( LLN plasma=3.2 nmol/hr/ml , LLN leucocytes=32 nmol/hr/mg/protein ) Females : historical genetic test result consistent Fabry mutation Globotriaosylceramide ( Gb3 ) concentration urine &gt; 1.5 time upper normal limit Patients never receive enzyme replacement therapy ( ERT ) past , patient receive ERT past 6 month negative anti alpha galactosidase antibody test eGFR ≥ 60 mL/min/1.73m2 The patient sign inform consent Female patient male patient whose copartner childbearing potential agree use medically acceptable method contraception , include rhythm method Participation trial investigational drug within 30 day prior study screen Chronic kidney disease stag 35 ( CKD 35 ) ( Appendix 7 ) History dialysis renal transplantation Angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB ) therapy initiate dose change 4 week prior screen Severe myocardial fibrosis MRI ( ≥2 lateenhancement [ LE ] positive leave ventricular segment ) ( Weidemann et al . 2009 ) History clinical stroke Pregnant nursing Presence HIV and/or HBsAg and/or Hepatitis C infection Known allergy ERT Known allergy Gadolinium base contrast agent Presence medical , emotional , behavioral psychological condition , judgment Investigator and/or Medical Director , would interfere patient 's compliance requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Fabry disease</keyword>
	<keyword>Alpha galactosidase deficiency</keyword>
	<keyword>Metabolic storage disease</keyword>
</DOC>